- Home
- SEVN vs IMUX Comparison
SEVN vs IMUX Comparison
Compare SEVN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | IMUX |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 209.2M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SEVN | IMUX |
|---|---|---|
| Price | $8.47 | $14.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.50 | ★ $36.00 |
| AVG Volume (30 Days) | 155.7K | ★ 169.8K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $44.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $0.51 |
| 52 Week High | $11.44 | $15.84 |
Technical Indicators
Market Signals| Indicator | SEVN | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 56.00 |
| Support Level | $8.33 | $0.74 |
| Resistance Level | $8.89 | $15.81 |
| Average True Range (ATR) | 0.22 | 0.87 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 32.93 | 30.52 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.